Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.20    -0.11 (-8.40%)
Bid:
1.10
Ask:
1.30
Spread: 0.20 (18.182%)
Market Cap: £10.27m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

Placing to raise £221,154

21 Feb 2025 07:00

RNS Number : 9430X
Tern PLC
21 February 2025
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

 

21 February 2025

 

Tern Plc

("Tern" or the "Company")

 

Placing to raise £221,154

 

Tern Plc (AIM:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things ("IoT") technology businesses, announces that it has raised £221,154, before expenses, through a placing of 19,230,769 new ordinary shares ("Ordinary Shares") of 0.02p each in the Company (the "Placing Shares") at a price of 1.15 pence per new Ordinary Share (the "Issue Price") (the "Placing"). The Placing is conditional upon the Placing Shares being admitted to trading on AIM ("Admission").

 

The Placing Shares will represent approximately 3.53 per cent. of the Company's enlarged issued share capital following the Placing. The Issue Price represents a discount of approximately 9.80 per cent. to the mid-market closing price of 1.275 pence per Ordinary Share on 20 February 2025, being the latest practicable business day prior to the publication of this announcement.

 

The net proceeds of the Placing are currently intended to be used to provide the Company with funds to:

 

· contribute towards Tern's commitment to invest in Sure Valley Ventures Enterprise Capital Fund ("SVV2" or the "Fund");

· provide additional support to Tern's portfolio as appropriate; and

· be applied towards general corporate purposes, including operating and legal expenses.

 

SVV2 is a venture capital fund that invests in a diverse portfolio of private UK software companies, with a particular emphasis on those in the immersive technology and metaverse sectors. This includes companies specialising in augmented and virtual reality, artificial intelligence and security.

 

As announced on 2 March 2022, Tern has previously committed to invest up to £5 million in SVV2 over the 10-year life of the Fund. Tern has a 6.1% holding in SVV2 which, as at 21 February 2025, had an unaudited valuation of approximately £750,000.

 

Shard Capital Partners LLP ("Shard Capital") acted as the Company's sole placing agent in respect of the Placing.

 

Update on SVV2

 

In conjunction with Tern's proposed funding of part of its commitment to SVV2, the Company is pleased to share the Fund's latest quarterly update, covering the period from 1 October 2024 to 31 December 2024.

 

SVV2 portfolio update

 

As of 31 December 2024, SVV2 has drawn down £16.56m, with £65.27m of undrawn commitments remaining.

 

During the quarter, the Fund made follow-on investments in RETìníZE Limited (£500k), which is a creative tech company, and Jaid (t/a Opsmatix Limited) (£800k), an AI-powered human communication solutions company.

 

Other key SVV2 portfolio holdings include Captur, Vortex IQ, and Ittybit, a Manchester-based investment made in June 2024.

 

New investments made in H2 2024

 

SVV2 expanded its portfolio with four new investments in H2 2024:

 

· in July 2024, the Fund invested £1m in Phinxt Robotics, an AI robotics startup;

· in August 2024, the Fund committed £1.5m to Purple Transform, an Oxford-based monitoring firm;

· also in August 2024, Stylus Education received £500k from the Fund for its AI-powered marking solution; and

· the Fund's final investment of the year, made in December 2024, was a £1m commitment to Vizgard, a drone security company, which received an initial £500k, with the option for a further £500k within six months.

 

Pipeline and deal flow

 

Looking ahead to 2025, SVV2 expects its most active year yet, targeting 6-8 new investments, alongside follow-on rounds, with anticipated drawdowns of 15-20% of the Fund.

 

At the time of the quarterly update the Fund was progressing five additional companies toward investment term sheets.

 

In addition, SVV2 has developed a strong investment pipeline. These opportunities have been sourced through a combination of inbound and outbound origination strategies, ensuring a steady flow of high-quality potential investments.

 

Admission and Total Voting Rights

 

The Placing has been conducted utilising the Directors' existing authorities to issue new Ordinary Shares. The Placing Shares will rank pari passu in all respects with the existing issued Ordinary Shares. The Placing is conditional, inter alia, on: i) there being no breach of the obligations under the Placing Agreement entered into between Shard Capital and the Company prior to Admission; and ii) Admission. Application has be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM. It is expected that Admission will become effective and that dealings in the Placing Shares on AIM will commence on or around 26 February 2025.

 

In accordance with the Financial Conduct Authority's Disclosure, Guidance and Transparency Rules, the Company confirms that following Admission, the Company's enlarged issued ordinary share capital will comprise 544,223,831 Ordinary Shares. The Company does not hold any shares in Treasury. Therefore, from Admission, the total number of voting rights in the Company will be 544,223,831 and from Admission this figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules.

 

Enquiries

 

Tern Plc

Ian Ritchie (Chairman)

via IFC Advisory

 

Allenby Capital Limited

(Nominated Adviser and Broker)

Alex Brearley / Dan Dearden-Williams (Corporate Finance)

Kelly Gardiner / Guy McDougall (Sales and Corporate Broking)

 

Tel: 0203 328 5656

 

IFC Advisory

(Financial PR and IR)

Tim Metcalfe

Graham Herring

Florence Chandler

 

Tel: 0203 934 6630

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESEMESSEISEEE
Date   Source Headline
8th Jun 20267:00 amRNSNotice of AGM
29th May 20265:00 pmRNSTotal Voting Rights
26th May 20267:00 amRNSInvestment in Talking Medicines CLNs
22nd May 20267:00 amRNSDevice Authority Convertible Loan Notes Investment
19th May 20267:00 amRNSPlacing to raise £222,000
12th May 20267:00 amRNS-RDevice Authority Strategic Partnership
8th May 202612:53 pmRNSResult of GM & Update on Open Offer
8th May 20267:00 amRNSResults of Open Offer
21st Apr 20267:00 amRNSOpen Offer and Notice of General Meeting
31st Mar 20265:00 pmRNSTotal Voting Rights
5th Mar 20267:00 amRNSExtension of loan facility agreement
3rd Mar 20267:00 amRNSResults of Open Offer
13th Feb 20267:00 amRNSOpen Offer at 0.40p to raise up to £384,408
5th Feb 20267:00 amRNS-RTern Notes Automotive Momentum at Device Authority
15th Jan 20267:00 amRNSUpdate regarding SVV2
8th Jan 20267:00 amRNSInvestor Presentations
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
12th Dec 20257:00 amRNSIssue of Talking Medicines Convertible Loan Notes
28th Nov 20257:00 amRNSUpdate regarding capital commitment to SVV2
25th Nov 20257:00 amRNSTalking Medicines CLN Modifications
31st Oct 20253:35 pmRNSTotal Voting Rights
15th Oct 20257:00 amRNSResults of Open Offer
9th Oct 20257:00 amRNSRemuneration Reductions & Distribution Commitment
29th Sep 20257:00 amRNSOpen Offer to raise up to £642,486
15th Sep 20257:00 amRNSExtension of Loan Facility Term
4th Sep 20257:00 amRNSInterim results for the six months to 30 June 2025
1st Sep 20257:00 amRNSAppointment of shareholder relations adviser
31st Jul 20254:34 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSResults of underwritten Open Offer & TVR
24th Jul 20257:00 amRNSReceipt of Bridging Loan
14th Jul 20257:00 amRNSUnderwritten Open Offer to raise £642,486
30th Jun 202512:07 pmRNSResult of AGM
13th Jun 20257:00 amRNSDirector Share Purchase
11th Jun 20257:00 amRNSDirector Share Purchase
6th Jun 20257:00 amRNSNotice of AGM and Director Retirement
5th Jun 20257:00 amRNSResults for the year ended 31 December 2024
30th May 20255:39 pmRNSTotal Voting Rights
7th May 20257:00 amRNSResults of Underwritten Open Offer
24th Apr 20257:00 amRNSPurple Transform appointment
17th Apr 20257:00 amRNSUnderwritten Open Offer to raise £340,140
11th Mar 20257:00 amRNS-RDevice Authority Microsoft & CyberArk Partnership
11th Mar 20257:00 amRNS-RSure Ventures Update
28th Feb 20255:00 pmRNSTotal Voting Rights
21st Feb 20257:00 amRNSPlacing to raise £221,154
14th Jan 20257:30 amRNS-RProgressive Equity Research Report
10th Jan 20257:00 amRNSInvestor Presentations
2nd Jan 20257:00 amRNSInvestment in Sure Ventures plc
31st Dec 20241:30 pmRNSTotal Voting Rights
23rd Dec 202411:39 amRNSDevice Authority update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.